文献速递哮喘

2型糖尿病合并哮喘患者使用GLP-1受体激动剂与哮喘急性发作的关系

Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

本研究基于电子健康记录,比较2型糖尿病合并哮喘成人启动GLP-1R激动剂与其他降糖药后哮喘急性发作情况。6个月时,GLP-1R激动剂组哮喘急性发作计数低于SGLT-2抑制剂、DPP-4抑制剂、磺脲类和基础胰岛素组,哮喘症状就诊也更少。提示GLP-1R激动剂可能成为代谢功能障碍相关哮喘的新治疗选择。

要点

  • 2型糖尿病合并哮喘患者使用GLP-1R激动剂,6个月哮喘急性发作计数低于其他降糖药。
  • GLP-1R激动剂组哮喘症状相关就诊次数也较少。
  • GLP-1R激动剂可能为代谢功能障碍相关哮喘提供新治疗方向。

核心结论

  • 成人2型糖尿病合并哮喘患者处方GLP-1R激动剂,哮喘急性发作计数低于启动其他降糖药者。

研究设计与样本

  • 基于电子健康记录的新用户、活性对照、回顾性队列研究,纳入2000年1月至2018年3月在某学术医疗系统新处方GLP-1R激动剂或对照药的2型糖尿病合并哮喘患者。
  • GLP-1R激动剂组448例,SGLT-2抑制剂组112例,DPP-4抑制剂组435例,磺脲类组2253例,基础胰岛素组2692例。

主要发现

  • 6个月时,以GLP-1R激动剂为参照,哮喘急性发作计数在SGLT-2抑制剂组IRR为2.98(95%CI 1.30-6.80)。
  • 6个月时,以GLP-1R激动剂为参照,哮喘急性发作计数在DPP-4抑制剂组IRR为2.45(95%CI 1.54-3.89)。
  • 6个月时,以GLP-1R激动剂为参照,哮喘急性发作计数在磺脲类组IRR为1.83(95%CI 1.20-2.77)。
  • 6个月时,以GLP-1R激动剂为参照,哮喘急性发作计数在基础胰岛素组IRR为2.58(95%CI 1.72-3.88)。
  • GLP-1R激动剂使用者因哮喘症状就诊的次数也较少。

临床怎么用

  • 对于2型糖尿病合并哮喘且需降糖治疗强化的成人,GLP-1R激动剂可能与较低的哮喘急性发作计数相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: GLP-1R (glucagon-like peptide-1 receptor) agonists are approved to treat type 2 diabetes mellitus and obesity. GLP-1R agonists reduce airway inflammation and hyperresponsiveness in preclinical models.Objectives: To compare rates of asthma exacerbations and symptoms between adults with type 2 diabetes and asthma prescribed GLP-1R agonists and those prescribed SGLT-2 (sodium-glucose cotransporter-2) inhibitors, DPP-4 (dipeptidyl peptidase-4) inhibitors, sulfonylureas, or basal insulin for diabetes treatment intensification.Methods: This study was an electronic health records-based new-user, active-comparator, retrospective cohort study of patients with type 2 diabetes and asthma newly prescribed GLP-1R agonists or comparator drugs at an academic healthcare system from January 2000 to March 2018. The primary outcome was asthma exacerbations; the secondary outcome was encounters for asthma symptoms. Propensity scores were calculated for GLP-1R agonist and non-GLP-1R agonist use. Zero-inflated Poisson regression models included adjustment for multiple covariates.Measurements and Main Results: Patients initiating GLP-1R agonists (n = 448), SGLT-2 inhibitors (n = 112), DPP-4 inhibitors (n = 435), sulfonylureas (n = 2,253), or basal insulin (n = 2,692) were identified. At 6 months, asthma exacerbation counts were lower in persons initiating GLP-1R agonists (reference) compared with SGLT-2 inhibitors (incidence rate ratio [IRR], 2.98; 95% confidence interval [CI], 1.30-6.80), DPP-4 inhibitors (IRR, 2.45; 95% CI, 1.54-3.89), sulfonylureas (IRR, 1.83; 95% CI, 1.20-2.77), and basal insulin (IRR, 2.58; 95% CI, 1.72-3.88). Healthcare encounters for asthma symptoms were also lower among GLP-1R agonist users.Conclusions: Adult patients with asthma prescribed GLP-1R agonists for type 2 diabetes had lower counts of asthma exacerbations compared with other drugs initiated for treatment intensification. GLP-1R agonists may represent a novel treatment for asthma associated with metabolic dysfunction.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Foer D, Beeler PE, Cui J, et al. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists. Am J Respir Crit Care Med. 2021. PMID: 33052715. doi:10.1164/rccm.202004-0993OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。